- Home
- ACHR vs MRVI Comparison
ACHR vs MRVI Comparison
Compare ACHR & MRVI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ACHR
- MRVI
- Stock Information
- Founded
- ACHR 2018
- MRVI 2020
- Country
- ACHR United States
- MRVI United States
- Employees
- ACHR N/A
- MRVI N/A
- Industry
- ACHR Aerospace
- MRVI Biotechnology: Pharmaceutical Preparations
- Sector
- ACHR Industrials
- MRVI Health Care
- Exchange
- ACHR Nasdaq
- MRVI Nasdaq
- Market Cap
- ACHR 1.3B
- MRVI 1.2B
- IPO Year
- ACHR N/A
- MRVI 2020
- Fundamental
- Price
- ACHR $6.03
- MRVI $5.22
- Analyst Decision
- ACHR Buy
- MRVI Buy
- Analyst Count
- ACHR 7
- MRVI 11
- Target Price
- ACHR $8.93
- MRVI $10.33
- AVG Volume (30 Days)
- ACHR 25.1M
- MRVI 2.6M
- Earning Date
- ACHR 11-07-2024
- MRVI 11-07-2024
- Dividend Yield
- ACHR N/A
- MRVI N/A
- EPS Growth
- ACHR N/A
- MRVI N/A
- EPS
- ACHR N/A
- MRVI N/A
- Revenue
- ACHR N/A
- MRVI $276,920,000.00
- Revenue This Year
- ACHR N/A
- MRVI N/A
- Revenue Next Year
- ACHR $2,048.97
- MRVI $7.10
- P/E Ratio
- ACHR N/A
- MRVI N/A
- Revenue Growth
- ACHR N/A
- MRVI N/A
- 52 Week Low
- ACHR $2.82
- MRVI $4.28
- 52 Week High
- ACHR $7.02
- MRVI $11.56
- Technical
- Relative Strength Index (RSI)
- ACHR 80.32
- MRVI 37.66
- Support Level
- ACHR $4.15
- MRVI $4.28
- Resistance Level
- ACHR $4.86
- MRVI $5.06
- Average True Range (ATR)
- ACHR 0.46
- MRVI 0.47
- MACD
- ACHR 0.21
- MRVI -0.09
- Stochastic Oscillator
- ACHR 93.83
- MRVI 23.54
About ACHR Archer Aviation Inc.
Archer Aviation Inc advances the benefits of sustainable air mobility. The company is engaged in designing and developing a fully electric vertical takeoff and landing eVTOL aircraft for use in UAM networks. It is creating an electric airline that moves people throughout cities in a quick, safe, sustainable, and cost-effective manner.
About MRVI Maravai LifeSciences Holdings Inc.
Maravai LifeSciences Holdings Inc is a life sciences company. It provides products to enable the development of drug therapies, diagnostics, and novel vaccines and supports research on human diseases. Its reportable segments are Nucleic acid production and biologics safety testing. It generates a majority of its revenue from Nucleic Acid Production and focuses on the manufacturing and sale of nucleic acid products to support the needs of customers' research, and therapeutic and vaccine programs. In addition, the segment also provides research products for labeling and detecting proteins in cells and tissue samples.